SV

Street Verdict

Analyst Scorecard

A record of what Sunil Subramaniam said publicly, with the source. Not advice.

Pending — not yet graded
“Bullish on the Pharma sector, seeing a rapid growth opportunity for India due to potential tariffs on Chinese API producers under Trumponomics. The sector is also expected to benefit from currency depreciation, making it a key focus from an external orientation perspective.”
Nifty PharmaBullishCalled 11 Feb 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Sunil Subramaniam’s full track record